Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Capital Expenditures (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Capital Expenditures for 4 consecutive years, with -$287000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 370.75% to -$287000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $169000.0 through Dec 2025, down 41.52% year-over-year, with the annual reading at $169000.0 for FY2025, 41.52% down from the prior year.
  • Capital Expenditures for Q4 2025 was -$287000.0 at Orchestra BioMed Holdings, down from $310000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $310000.0 in Q3 2025, with the low at -$287000.0 in Q4 2025.
  • Average Capital Expenditures over 4 years is $70437.5, with a median of $50500.0 recorded in 2022.
  • The sharpest move saw Capital Expenditures surged 3633.33% in 2024, then crashed 370.75% in 2025.
  • Over 4 years, Capital Expenditures stood at $54000.0 in 2022, then tumbled by 105.56% to -$3000.0 in 2023, then soared by 3633.33% to $106000.0 in 2024, then plummeted by 370.75% to -$287000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at -$287000.0, $310000.0, and $34000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.